Search
for
Sort by
Research 30 of 96
- Nano-PROTACs: state of the art and perspectives
- NDA Submission of Vepdegestrant (ARV-471) to U.S. FDA: The Beginning of a New Era of PROTAC Degraders
- PROTACs: A novel strategy for cancer drug discovery and development
- Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions
- Expanding the Scope of PROTACs: Opportunities and Challenges in Topical Delivery
- PROTACs in 2025: from the laboratory concept to clinical breakthrough
- PROTACs in cancer therapy: targeted degradation of GPX4, PARP and epigenetic regulators
- A Top-Down Design Approach for Generating a Peptide PROTAC Drug Targeting Androgen Receptor for Androgenetic Alopecia Therapy
- PROTAC Degraders of Androgen Receptor‐Integrated Dissolving Microneedles for Androgenetic Alopecia and Recrudescence Treatment via Single Topical Administration
- Advancing PROTAC therapeutics through chemistry-guided design of smart delivery systems
- Discovery of a Novel Non-invasive AR PROTAC Degrader for the Topical Treatment of Androgenetic Alopecia
- MEGA PROTAC, MEGA DOCK-based PROTAC mediated ternary complex formation pipeline with sequential filtering and rank aggregation
- Nanoliposomal Co-Delivery of AR-PROTAC and NFKBIZ siRNA for Synergistic Therapy of Androgenetic Alopecia
- Emerging Strategies in Smart Nano-PROTAC for Stimuli-Responsive Protein Degradation and Precision Cancer Therapy
- Advancing Design Strategy of PROTACs for Cancer Therapy
- Peptide-Based PROTACs: Transitioning from Static Paradigm to a Dynamic Landscape within Targeted Protein Degradation
- Enriching Proteolysis Targeting Chimeras with a Second Modality: When Two Are Better Than One
- Proteolysis‐targeting chimeras in cancer therapy: Targeted protein degradation for next‐generation treatment
- Evolving CRBN ligands enhance the drug-like properties of protein degraders
- Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique
- Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer
- Discovery of an Androgen Receptor Degrader Featuring a Pyridazinyl Glutarimide CRBN-Binding Motif for Transdermal Treatment of Androgenetic Alopecia
- Next Generation Therapeutics for Androgenetic Alopecia
- ADVANCEMENTS IN TREATMENT STRATEGIES FOR ANDROGENETIC ALOPECIA: NOVEL THERAPIES AND FUTURE PERSPECTIVES
- Methodologic considerations in evaluating early clinical outcomes of GT20029 for androgenetic alopecia
- Clinical Translation of Targeted Protein Degraders
- De novo designed bifunctional proteins for targeted protein degradation
- <i>De novo</i> designed bifunctional proteins for targeted protein degradation
- Targeted protein degradation of Wnt/β-catenin signaling pathway: an effective strategy for cancer therapy
- Advances in clinical applications of microneedle